Showing results (481-490 of 760) with videos related to
Sort By:
Pageof 76
Blood|January 5, 2013
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemiaIrene M Ghobrial, Federico Campigotto, Timothy J Murphy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
A global expression-based analysis of the consequences of the t(4;14) translocation in myelomaAnn M Dring, Faith E Davies, James A L Fenton, et al.British Journal of Haematology|April 3, 2015
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantationMathew Weinstock, Yosra Aljawai, Elizabeth A Morgan, et al.Cell Reports|December 28, 2018
Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple MyelomaMariateresa Fulciniti, Charles Y Lin, Mehmet K Samur, et al.Blood|January 11, 2023
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myelomaTing Du, Yan Song, Arghya Ray, et al.Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.Cancer Research|September 10, 2009
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cellsMala Mani, Daniel E Carrasco, Yunyu Zhang, et al.European Journal of Haematology|February 4, 2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomibPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupMehmet Kemal Samur, Anil Aktas Samur, Mariateresa Fulciniti, et al.American Journal of Hematology|July 24, 2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström MacroglobulinemiaIrene M Ghobrial, Wanling Xie, Swaminathan Padmanabhan, et al.Pageof 76